Should the bupropion (Wellbutrin) be reduced to 150 mg daily or discontinued in a patient who became suicidal on 300 mg but was stable on 150 mg, given that the patient refuses selective serotonin reuptake inhibitors (SSRIs)?

Reduce Wellbutrin to 150 mg Daily and Continue Treatment

Given that the patient was stable on 150 mg but became suicidal on 300 mg, reduce the dose back to 150 mg daily rather than discontinuing entirely. This approach maintains antidepressant coverage while eliminating the dose-related suicidal ideation, particularly important since the patient refuses SSRIs.

Rationale for Dose Reduction vs. Discontinuation

The FDA labeling for Wellbutrin XL explicitly supports dose reduction as a management strategy. When discontinuing 300 mg daily, the label specifically instructs to "decrease the dose to 150 mg once daily prior to discontinuation" 1. This graduated approach is standard practice and demonstrates that 150 mg is a recognized therapeutic dose distinct from 300 mg.

The patient's clinical history provides clear evidence that 150 mg was therapeutic without suicidal ideation, while 300 mg triggered suicidality. This dose-response relationship strongly suggests the suicidal thoughts were medication-induced rather than disease-related, making dose reduction the logical intervention rather than complete discontinuation.

Critical Safety Considerations

Immediate Risk Assessment

• The emergence of suicidal ideation at 300 mg requires urgent dose reduction back to 150 mg
• Monitor closely for the first 2-4 weeks after dose adjustment, as withdrawal symptoms can mimic or worsen depression 2
• Implement a crisis response plan that includes specific warning signs, emergency contacts, and coping strategies 3

Distinguishing Withdrawal from Relapse

When reducing from 300 mg to 150 mg, watch for:

• Withdrawal symptoms (typically emerge within 1-5 days): flu-like symptoms, electric shock sensations, dizziness, irritability
• Relapse symptoms (typically emerge after 2+ weeks): persistent low mood, anhedonia, neurovegetative symptoms

If concerning symptoms emerge during the taper, the dose reduction may need to be more gradual, though bupropion generally has lower withdrawal risk than SSRIs 2.

Dosing Protocol

Per FDA labeling, the standard approach for MDD is:

• Start at 150 mg once daily in the morning
• May increase to 300 mg after 4 days if needed 1

In this case, reverse this process:

• Immediately reduce from 300 mg to 150 mg once daily
• Continue 150 mg indefinitely as maintenance therapy
• The FDA label confirms that "it is unknown whether the Wellbutrin XL dose needed for maintenance treatment is identical to the dose that provided an initial response" 1, supporting the use of 150 mg long-term if clinically effective

Why Not Discontinue Completely?

Stopping bupropion entirely would leave the patient without antidepressant coverage, and they refuse SSRIs. The evidence shows:

• Bupropion 150 mg daily is an established therapeutic dose for MDD 4, 5
• The patient had a positive response at this dose previously
• Acute depressive episodes require several months of treatment beyond initial response 1

Complete discontinuation risks precipitating a depressive relapse, which itself carries suicide risk 3. Since the patient was stable on 150 mg, this dose provides ongoing depression management without the suicidality seen at 300 mg.

Alternative Antidepressant Options (If Needed)

If 150 mg proves insufficient for depression control over time, consider:

• Mirtazapine or nefazodone: Non-SSRI alternatives with different mechanisms 6
• Augmentation strategies: Though the patient refuses SSRIs, other augmenting agents could be considered if depression worsens
• Psychotherapy: CBT or DBT have strong evidence for reducing suicidal ideation and should be implemented regardless of medication choice 3

Monitoring Plan

• Week 1-2: Contact every 2-3 days to assess suicidal ideation resolution
• Week 3-4: Weekly visits to confirm stability and screen for withdrawal vs. relapse
• Month 2-3: Biweekly visits to ensure sustained response at 150 mg
• Ongoing: Monthly follow-up with standardized depression rating scales (PHQ-9 or similar)

The key principle: the patient's own clinical response provides the clearest evidence that 150 mg is therapeutic while 300 mg is harmful. Respect this dose-response relationship rather than abandoning a medication that worked at the lower dose.